IB Parks & Entertainment has expanded its family entertainment portfolio with the acquisition of Big Kahuna’s Water Park in West Berlin, New Jersey. This year-round water park, previously known as Sahara Sam’s Oasis, features over 70,000 square feet of indoor and outdoor attractions. The acquisition aligns with IB Parks & Entertainment’s growth strategy and offers opportunities for collaboration with its nearby Clementon Park location.
Hoyer, a global leader in energy-efficient motor solutions, has acquired NowiTek, an automation solutions developer. This acquisition strengthens Hoyer’s commitment to providing advanced, automated solutions that save energy and reduce costs. NowiTek’s SCADA software platform will be integrated into Hoyer’s Advanced Solutions portfolio, expanding its capabilities in various industries.
Qualcomm’s interest in acquiring Intel appears to be cooling due to the complexities of such a large-scale merger. While a full acquisition may be off the table for now, Qualcomm hasn’t ruled out purchasing parts of Intel or revisiting the idea later. This development comes as Intel faces financial headwinds, including reduced CHIPS Act funding and slower-than-expected AI chip sales.
McAdams, a leading multidisciplinary design and engineering firm, announces the acquisition of AVID Group, LLC, a prominent Central Florida civil engineering firm. This strategic move significantly strengthens McAdams’ presence in the Southeast, particularly in the thriving Orlando and Tampa markets, enhancing its service capabilities for existing and new clients.
Just Eat Takeaway.com (JTKWY) has announced the sale of its US food delivery business, Grubhub, to Wonder Group for an enterprise value of $650 million. This move comes after investor pressure to divest Grubhub and is expected to generate up to $50 million in net proceeds for Just Eat Takeaway. The transaction is slated for completion in the first quarter of 2025, subject to regulatory approval. This sale aims to improve Just Eat’s financial health, support investments in key markets, and enhance its cash flow.
Verdantas, a leading environmental consulting firm, has acquired Groundwater Sciences Corporation (GSC), a renowned environmental assessment and remediation company, strengthening its presence and expertise in the Northeast. This strategic acquisition adds a team of highly skilled professionals with deep expertise in geology, hydrogeology, and contaminant hydrology, enabling Verdantas to provide enhanced services for clients in the region.
The ongoing conflict in Ukraine has significantly impacted India’s defense procurement plans from Russia, causing substantial delays in the delivery of key systems, including air defense systems, warships, and submarines. This article explores the ramifications of these delays and analyzes their implications for India’s strategic posture.
CrowdStrike Holdings, Inc. (CRWD) continues to expand its cybersecurity reach, announcing a partnership with Ignition Technology in Ireland, launching AI Red Team Services to protect AI systems, and acquiring Adaptive Shield to enhance identity-based security. These strategic moves underscore CrowdStrike’s commitment to delivering comprehensive, AI-powered cybersecurity solutions to organizations worldwide.
BCE, Inc. (BCE) stock is experiencing a significant decline on Monday after the company’s subsidiary, Bell Canada, announced the acquisition of Ziply Fiber and a pause in dividend growth. This strategic move aims to expand Bell’s fiber network into the United States, adding over 1.3 million fiber locations and bolstering its position as North America’s third-largest fiber internet provider.
Lyell Immunopharma Inc. (LYEL) has acquired ImmPACT Bio USA Inc., a clinical-stage biotechnology company, for $30 million in cash and 37.5 million Lyell shares. This acquisition brings IMPT-314, a CAR T-cell therapy, to Lyell’s pipeline, but analysts are concerned about the complexities and potential distractions it introduces. Lyell is also discontinuing several programs, including LYL797 and LYL845, to focus on its most differentiated CAR T-cell therapies and the upcoming Phase 1 clinical trial of LYL119. Despite the strategic shift, analysts remain cautious about Lyell’s future due to increased competition and the uncertainty surrounding IMPT-314’s clinical benefits.
